Alois Gratwohl

List of Publications by Year
in descending order

116 papers	8,498 citations	172457 29 h-index	43889 91 g-index
118 all docs	118 docs citations	118 times ranked	8363 citing authors

#	Article	IF	Citations
1	Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. British Journal of Haematology, 2021, 192, e151-e154.	2.5	3
2	Cost-effectiveness of defibrotide for treatment of severe veno-occlusive disease: It is time for evidence based economic evaluations. Journal of Medical Economics, 2021, 24, 1-1.	2.1	3
3	Visions for a JACIE Quality Management System 4.0. Bone Marrow Transplantation, 2021, 56, 2876-2881.	2.4	3
4	Ruxolitinib for Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2021, 385, 1631-1632.	27.0	2
5	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplantation, 2020, 55, 126-136.	2.4	196
6	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 2020, 55, 681-694.	2.4	39
7	Gender gaps in transplantation. British Journal of Haematology, 2020, 190, e123-e125.	2.5	0
8	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplantation, 2019, 54, 402-417.	2.4	31
9	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine, 2019, 15, 33-41.	7.1	8
10	The EBMT: History, Present, and Future. , 2019, , 11-17.		8
11	High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels. Blood, 2019, 134, 666-666.	1.4	2
12	Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. Blood, 2017, 130, 897-897.	1.4	7
13	Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).. Journal of Clinical Oncology, 2017, 35, 7049-7049.	1.6	0
14	The Role of Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia. Hematologic Malignancies, 2016, , 177-196.	0.2	1
15	Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA - Journal of the American Medical Association, 2016, 315, 198.	7.4	18
16	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Annals of Hematology, 2016, 95, 967-972.	1.8	6
17	Gender and Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1145-1146.	2.0	11
18	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. EBioMedicine, 2015, 2, 2101-2109.	6.1	36

#	Article	IF	Citations
19	Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013. BMJ Open, 2015, 5, e007021-e007021.	1.9	12
20	One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematology,the, 2015, 2, e91-e100.	4.6	329
21	HY: Foe or Maybe Friend?. Biology of Blood and Marrow Transplantation, 2015, 21, 580-582.	2.0	2
22	The role of hematopoietic stem cell transplantation in chronic myeloid leukemia. Annals of Hematology, 2015, 94, 177-186.	1.8	15
23	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	7.6	128
24	Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?. Biology of Blood and Marrow Transplantation, 2015, 21, 1230-1236.	2.0	35
25	Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. Haematologica, 2014, 99, 908-915.	3.5	83
26	DEVELOPMENT OF COVERAGE WITH EVIDENCE DEVELOPMENT FOR MEDICAL TECHNOLOGIES IN SWITZERLAND FROM 1996 TO 2012. International Journal of Technology Assessment in Health Care, 2014, 30, 253-259.	0.5	6
27	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	7.4	566
28	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1367-1381.	2.5	5
29	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood, 2014, 124, 2596-2606.	1.4	228
30	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica, 2013, 98, 1282-1290.	3.5	110
31	Hematopoietic stem cell transplantation activity in Europe. Current Opinion in Hematology, 2013, 20, 485-493.	2.5	53
32	Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Medical Weekly, 2013, 143, w13757.	1.6	4
33	Use Of a Quality Management System and Outcome After Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 2945-2945.	1.4	1
34	Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease. Chest, 2012, 142, 988-995.	0.8	17
35	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews Clinical Oncology, 2012, 9, 579-590.	27.6	352
36	History of Hematopoietic Stem Cell Transplantation: Evolution and Perspectives. Current Problems in Dermatology, 2012, 43, 81-90.	0.7	20

#	Article	IF	Citations
37	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. Blood, 2012, 120, 964-964.	1.4	5
38	Cord blood meets its match. Lancet Oncology, The, 2011, 12, 1177-1178.	10.7	2
39	Introduction of a Quality Management System and Outcome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 1980-1986.	1.6	85
40	Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab. Blood, 2011, 118, 1555-1555.	1.4	1
41	Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap. Blood, 2011, 118, 1016-1016.	1.4	1
42	Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML. Blood, 2011, 118, 2030-2030.	1.4	0
43	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40â€“60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. Blood, 2011, 118, 159-159.	1.4	1
44	Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica, 2010, 95, 637-643.	3.5	42
45	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, 115, 1880-1885.	1.4	198
46	ThomasÃ¢Â€Â™ Hematopoietic Cell Transplantation. European Journal of Haematology, 2010, 84, 95-95.	2.2	5
47	Hematopoietic Stem Cell Transplantation<subtitle>A Global Perspective</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1617.	7.4	556
48	European survey on clinical use of cord blood for hematopoietic and non-hematopoietic indications. Transfusion and Apheresis Science, 2010, 42, 265-275.	1.0	16
49	Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV. Blood, 2010, 116, 357-357.	1.4	5
50	Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy: Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission. Blood, 2010, 116, 367-367.	1.4	2
51	Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT.. Blood, 2010, 116, 4558-4558.	1.4	1
52	Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV. Blood, 2010, 116, 669-669.	1.4	4
53	Bortezomib(VelcadeÂ®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation. Blood, 2010, 116, 3043-3043.	1.4	1
54	Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.. Blood, 2010, 116, 3461-3461.	1.4	0

#	Article	IF	Citations
55	Prophylaxis and Treatment of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation: A Survey on Center Strategies by the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2010, 116, 1261-1261.	1.4	1
56	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. Blood, 2010, 116, 2348-2348.	1.4	1
57	Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer, 2009, 115, 4715-4726.	4.1	337
58	Current role of stem cell transplantation in chronic myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2009, 22, 431-443.	1.7	46
59	Trends of hematopoietic stem cell transplantation in the third millennium. Current Opinion in Hematology, 2009, 16, 420-426.	2.5	43
60	Dermatologic manifestations of hematopoietic stem cell transplantation: understanding and management. Expert Review of Dermatology, 2009, 4, 637-654.	0.3	2
61	Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).. Blood, 2009, 114, 1181-1181.	1.4	1
62	Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.. Blood, 2009, 114, 339-339.	1.4	16
63	High-Dose Melphalan Re-Induction with or without Stem Cell Support Prior to Myeloablative Allogeneic Stem Cell Transplantation in Patients with Advanced Relapsed or Refractory Acute Myeloid Leukemia.. Blood, 2009, 114, 2271-2271.	1.4	0
64	Cyclosporine Levels and Rate of Graft Rejection Following Reduced Intensity Conditioning.. Blood, 2009, 114, 3337-3337.	1.4	0
65	T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective EBMT Analysis.. Blood, 2009, 114, 2307-2307.	1.4	4
66	The Bidirectional Relationship Between Cytomegalovirus Replication and Graft-Versus-Host Disease - a Retrospective Single Center Study.. Blood, 2009, 114, 2236-2236.	1.4	11
67	Clinical and Genetic Risk Assessment for Overall Survival in Haematopoietic Stem Cell Transplantation (HSCT).. Blood, 2009, 114, 1189-1189.	1.4	0
68	Hematopoietic Stem Cell Transplantation: a Global Perspective From the Worldwide Network of Blood and Marrow Transplantation.. Blood, 2009, 114, 809-809.	1.4	3
69	Common Myeloid Progenitor Content in Allogeneic Graft Products Correlates with Time to Platelet Engraftment.. Blood, 2009, 114, 3215-3215.	1.4	0
70	Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 2268-2268.	1.4	0
71	H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet, The, 2008, 372, 49-53.	13.7	121
72	Allogeneic hematopoietic stem cell transplantation for severe autoimmune diseases. Autoimmunity, 2008, 41, 673-678.	2.6	7

#	Article	IF	Citations
73	Role of allogeneic transplantation in chronic myeloid leukemia. Expert Review of Hematology, 2008, 1, 41-50.	2.2	3
74	Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Blood, 2008, 112, 164-164.	1.4	3
75	Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV. Blood, 2008, 112, 184-184.	1.4	8
76	Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies. Blood, 2008, 112, 2963-2963.	1.4	12
77	Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse of Malignant Disease: Retrospective Analysis of Outcome and Predictive Factors. Blood, 2008, 112, 339-339.	1.4	1
78	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. Blood, 2008, 112, 448-448.	1.4	3
79	Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT. Blood, 2008, 112, 793-793.	1.4	4
80	Late Altered Organ Function in Long Term Survivors after Allogeneic HSCT: A Paired Comparison with Their Identical Sibling Donor. Blood, 2008, 112, 4298-4298.	1.4	2
81	Expansion of Donor NK Cells for Adoptive Immunotherapy in Haploidentical Stem Cell Transplantation: A Phase Iâ€“II Study. Blood, 2008, 112, 3893-3893.	1.4	0
82	Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.. Blood, 2008, 112, 1968-1968.	1.4	0
83	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 2007, 109, 4686-4692.	1.4	141
84	Activity Survey and Historical Perspective of Autologous Stem Cell Transplantation in Europe. Seminars in Hematology, 2007, 44, 220-226.	3.4	10
85	Risk assessment in haematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2007, 20, 119-124.	1.7	9
86	Predictability of hematopoietic stem cell transplantation rates. Haematologica, 2007, 92, 1679-1686.	3.5	32
87	The Combination of 2-CDA and Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL): A Prospective Multicenter Phase II Trial (SAKK 34/02).. Blood, 2007, 110, 2057-2057.	1.4	11
88	Severe Donor Events after Allogeneic Hematopoietic Stem Cell Donation.. Blood, 2007, 110, 3276-3276.	1.4	1
89	Impact of the Donor Recipient Sex Combination in Hematopoietic Stem Cell Transplantation: H-Y as a Model for the Interaction between Major and Minor Histocompatibility Antigens.. Blood, 2007, 110, 481-481.	1.4	2
90	Premature Aging of Hematopoietic Cells in Long Term Survivors after HSCT with Chronic GVHD and a Female Donor.. Blood, 2007, 110, 829-829.	1.4	1

#	Article	IF	Citations
91	Transplant Centre Experience and Patient Selection Are the Key Elements Associated with Outcome of RIC and MAC HSCT for CML.. Blood, 2007, 110, 478-478.	1.4	0
92	The JAK2-V617F Mutation Load Remains Stable over Several Years in Most Patients with Myeloproliferative Disorders Analyzed in a Retrospective Single Center Study.. Blood, 2007, 110, 2526-2526.	1.4	1
93	Costs of Imatinib, Costs of Transplants and Gross National Income Per Capita Impact on Transplant Rates for Chronic Myeloid Leukemia in European Countries.. Blood, 2006, 108, 2979-2979.	1.4	6
94	Preemptive Immunotherapy with Highly Purified CD56+/CD3â^' Natural Killer Cells after Haploidentical Stem Cell Transplantation. A Prospective Phase II Study in 2 Centers.. Blood, 2006, 108, 411-411.	1.4	0
95	High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.. Blood, 2006, 108, 5352-5352.	1.4	0
96	Chronic GVHD Leads to Shortening of Telomeres in Subsets of Lymphoid Cells but Not in Granulocytes in Long-Term Survivors after Allogeneic HSCT.. Blood, 2006, 108, 2872-2872.	1.4	0
97	Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 2006, 91, 513-21.	3.5	184
98	Does early stem-cell transplantation have a role in chronic myeloid leukaemia?. Lancet Oncology, The, 2005, 6, 721-723.	10.7	8
99	Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Alone.. Blood, 2005, 106, 141-141.	1.4	4
100	Sideroblastic Changes Can Be Recognized in the Erythrogram.. Blood, 2005, 106, 4909-4909.	1.4	0
101	Birth Order and Outcome in HLA-Identical Sibling Donor Hematopoietic Stem Cell Transplants. Impact of a Sequential Fetomaternal - Maternofetal Cell Transfer?.. Blood, 2005, 106, 2034-2034.	1.4	0
102	Hematopoietic Precursor Cell Cultures (CFU-C) in Diagnosis and Prognosis of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).. Blood, 2005, 106, 4918-4918.	1.4	0
103	Abandoning Care in Laminar Air Flow (LAF) Units and Routine High Dose Intravenous Immunoglobulines (IVIG) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Does Not Increase Mortality and Rate of Infections.. Blood, 2004, 104, 5072-5072.	1.4	2
104	Impact of Molecular HLA Matching for Allogeneic Stem Cell Transplantation from Unrelated Donors.. Blood, 2004, 104, 979-979.	1.4	1
105	Donor Hematopoietic Stem Cells Did No Major Contribution to Hair Follicle Repair Either in Short or in Long Term Allogeneic Hematopoietic Stem Cell Transplants Recipients.. Blood, 2004, 104, 4167-4167.	1.4	0
106	Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croatian Medical Journal, 2004, 45, 689-94.	0.7	16
107	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 348, 994-1004.	27.0	3,227
108	Stable Transduction with Lentiviral Vectors and Amplification of Immature Hematopoietic Progenitors from Cord Blood of Preterm Human Fetuses. Human Gene Therapy, 2001, 12, 377-389.	2.7	35

#	Article	IF	Citations
109	Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. The Hematology Journal, 2001, 2, 363-370.	1.4	118
110	Microchimerism: Friend or foe?. Nature Medicine, 1998, 4, 386-388.	30.7	13
111	Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Diseases. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 885-890.	5.6	105
112	Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow Transplantation. New England Journal of Medicine, 1996, 334, 281-285.	27.0	571
113	Evaluation of the Sysmex R-1000Â®: An Automated Reticulocyte Analyzer. American Journal of Clinical Pathology, 1990, 93, 70-78.	0.7	62
114	Complete recovery of marrow function after treatment with anti-lymphocyte globulin is associated with high, whereas early failure and development of paroxysmal nocturnal haemoglobinuria are associated with low endogenous G-CSA-release. British Journal of Haematology, 1989, 72, 573-577.	2.5	16
115	Bottled Lemon Juice -- A Cryptic Source of Invasive Candida Infections in the Immunocompromised Host. Journal of Infectious Diseases, 1988, 158, 654-655.	4.0	14
116	Experimental immunologically mediated aplastic anemia (AA) in mice: Cyclosporin a fails to protect against AA. International Journal of Cell Cloning, 1984, 2, 263-271.	1.6	7